The Qatar Investment Authority (QIA) has invested in a $132 million Series B funding round for Artbio, a US-based radiopharmaceutical company developing alpha radioligand therapies for cancer treatment.
This is QIA’s first investment in Artbio, which is in the clinical stage of developing a new class of targeted cancer therapies. The round was led by Sofinnova Investments and B Capital, along with a returning life sciences investor. Existing backers F-Prime Capital, Omega Funds, and Third Rock Ventures also participated, along with new investor Alexandria Venture Investments.
Artbio said the funds will support the advancement of its clinical pipeline of alpha radioligand therapies (ARTs). The company is among a growing number of biotech firms focusing on targeted cancer treatments using radioisotopes.
QIA, which manages assets worth $524 billion, has been expanding its exposure to the US biotech sector. In 2023, it led a $250 million funding round in BridgeBio Pharma, a Nasdaq-listed company working on treatments for genetic diseases and cancers.
The investment aligns with QIA’s broader strategy of increasing allocations to healthcare and life sciences as part of its global portfolio diversification.
